Company intelligence / Profile preview

杭州和正医药

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Hezheng Pharma is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on high-growth therapeutic areas including oncology, autoimmune diseases, and metabolic disorders. Its lead candidate, HZ-A-018, is a selective JAK1 inhibitor undergoing clinical trials for multiple inflammatory conditions such as atopic dermatitis and rheumatoid arthritis. Hezheng Pharma leverages its internal R&D capabilities to build a diverse pipeline of targeted therapies, including BTK and KRAS inhibitors. The company aims to provide high-quality, affordable innovative medicines to patients globally.

Therapeutic areas: OncologyRheumatologyDermatologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 杭州和正医药.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 杭州和正医药.

Explore the full profile